Correlation between serum RANTES levels and the severity of Parkinson's disease

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Tang, Peng ^a   Chong, Li ^a   Li, Xiaoqing ^a   Liu, Yue ^a   Liu, Peng ^a   Hou, Chen ^a   Li, Rui ^a  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; DISEASES; T-CELLS;

CHEMOKINE LIGANDS; INFLAMMATORY MEDIATORS; INTERLEUKIN-6; NEURODEGENERATIVE; PARKINSON'S DISEASE; SERUM LEVELS; SYSTEMIC INFLAMMATION;

NEURODEGENERATIVE DISEASES;

ANTIPARKINSON AGENT; INTERLEUKIN 6; RANTES; CCL5 PROTEIN, HUMAN;

AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; RANTES BLOOD LEVEL; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; PATHOLOGY;

AGED; CHEMOKINE CCL5; FEMALE; HUMANS; MALE; PARKINSON DISEASE;

EID: 84920520147     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/208408     Document Type: Article

References (21)

1. O. Aktas, O. Ullrich, C. Infante-Duarte, R. Nitsch, and F. Zipp, "Neuronal damage in brain inflammation," Archives of Neurology, vol. 64, no. 2, pp. 185-189, 2007.
2. P. L. McGeer and E. G. McGeer, "Glial reactions in Parkinsons disease," Movement Disorders, vol. 23, no. 4, pp. 474-483, 2008.
3. Y. C. Chung, H. W. Ko, E. Bok et al., "The role of neuroinflammation on the pathogenesis of Parkinsons disease," BMB Reports, vol. 43, no. 4, pp. 225-232, 2010.
4. R. L. Miller, M. James-Kracke, G. Y. Sun, and A. Y. Sun, "Oxidative and inflammatory pathways in Parkinsons disease," Neurochemical Research, vol. 34, no. 1, pp. 55-65, 2009.
5. H. Chen, E. J. OReilly, M. A. Schwarzschild, and A. Ascherio, "Peripheral inflammatory biomarkers and risk of Parkinsons disease," American Journal of Epidemiology, vol. 167, no. 1, pp. 90-95, 2008.
6. V. Appay and S. L. Rowland-Jones, "RANTES: a versatile and controversial chemokine," Trends in Immunology, vol. 22, no. 2, pp. 83-87, 2001.
7. M. Xia and B. T. Hyman, "Chemokines/chemokine receptors in the central nervous system and Alzheimers disease," Journal of NeuroVirology, vol. 5, no. 1, pp. 32-41, 1999.
8. L. Cartier, O. Hartley, M. Dubois-Dauphin, and K.-H. Krause, "Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases," Brain Research Reviews, vol. 48, no. 1, pp. 16-42, 2005.
9. D. Galimberti, N. Schoonenboom, P. Scheltens et al., "Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease," Archives of Neurology, vol. 63,no. 4, pp. 538- 543, 2006.
10. P. Scalzo, A. Kümmer, F. Cardoso, and A. L. Teixeira, "Increased serumlevels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinsons disease," Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 122-125, 2009.
11. K. Varani, F. Vincenzi, A. Tosi et al., "A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinsons disease," The FASEB Journal, vol. 24, no. 2, pp. 587-598, 2010.
12. K. W. Hofmann, A. F. S. Schuh, J. Saute et al., "Interleukin-6 serum levels in patients with parkinsons disease," Neurochemical Research, vol. 34, no. 8, pp. 1401-1404, 2009.
13. P. Scalzo, A. Kümmer, F. Cardoso, and A. L. Teixeira, "Serum levels of interleukin-6 are elevated in patients with Parkinsons disease and correlate with physical performance," Neuroscience Letters, vol. 468, no. 1, pp. 56-58, 2010.
14. M. Rentzos, C. Nikolaou, E. Andreadou et al., "Circulating interleukin-10 and interleukin-12 in Parkinsons disease," Acta Neurologica Scandinavica, vol. 119, no. 5, pp. 332-337, 2009.
15. M. Rentzos, C. Nikolaou, A. Rombos et al., "Rantes levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis," Amyotrophic Lateral Sclerosis, vol. 8, no. 5, pp. 283-287, 2007.
16. M. Reale, C. Iarlori, A. Thomas et al., "Peripheral cytokines profile in Parkinsons disease," Brain, Behavior, and Immunity, vol. 23, no. 1, pp. 55-63, 2009.
17. A. J. Antczak, J. A. Vieth, N. Singh, and R. G.Worth, "Internalization of IgG-coated targets results in activation and secretion of soluble CD40 ligand and rantes by human platelets," Clinical and Vaccine Immunology, vol. 18, no. 2, pp. 210-216, 2011.
18. M. Dettke,M. Dreer, P. Höcker, and S. Panzer, "Human platelet antigen-1a antibodies induce the release of the chemokine RANTES from human platelets," Vox Sanguinis, vol. 81, no. 3, pp. 199-203, 2001.
19. M. Rentzos, C. Nikolaou, E. Andreadou et al., "Circulating interleukin-15 and RANTES chemokine in Parkinsons disease," Acta Neurologica Scandinavica, vol. 116, no. 6, pp. 374-379, 2007.
20. N. J. Diederich, C. G. Moore, S. E. Leurgans, T. A. Chmura, and C. G. Goetz, "Parkinson diseasewith old-age onset: a comparative study with subjects with middle-age onset," Archives of Neurology, vol. 60, no. 4, pp. 529-533, 2003.
21. M. Richards, K. Marder, L. Cote, and R. Mayeux, "Interrater reliability of the unified parkinsons disease rating scale motor examination," Movement Disorders, vol. 9, no. 1, pp. 89-91, 1994.